Bella Pharmaceuticals Recalls PF-Glutathione Vials Due to Sterility Concerns
Bella Pharmaceuticals is recalling 82 vials of PF-Glutathione 200mg/ml because the product lacks assurance of sterility.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe severity score under the rubric for drug recalls involving potential serious health consequences.
Plain-English summary
Bella Pharmaceuticals, Inc. is recalling 82 vials of PF-Glutathione 200mg/ml, 30 mL vials, which are prescription-only products. The recall was initiated because the product lacks assurance of sterility.
The affected product is identified by Lot # 070617GL with an expiration date of 1/6/18. The recall covers distribution nationwide within the USA.
Consumers and healthcare providers should stop using the affected product and contact their healthcare provider or the recalling firm for further instructions.
The recalled product
- Product
- PF-Glutathione 200mg/ml, 30 mL vials, Rx only, Bella Pharma 3101 W. Devon Ave., Chicago, IL 60659 1 (877) BELLA.
- Manufacturer
- Bella Pharmaceuticals, Inc.
- Category
- Drug — Injectable
- Hazard
- Affected units
- 82
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 070617GL
- Exp. 1/6/18
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 16 recalled by Bella Pharmaceuticals, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 16 products in this recall →Related recalls
Same manufacturer · Bella Pharmaceuticals, Inc.
See all →- SevereBella Pharmaceuticals Recalls Mannitol 20% Vials Due to Sterility Concerns
FDA (Drugs) · 2017-09-20
- SevereBella Pharmaceuticals Recalls B-Complex Vials Due to Sterility Concerns
FDA (Drugs) · 2017-09-20
- SevereBella Pharmaceuticals Recalls Fluorescein Sodium Vials Due to Sterility Concerns
FDA (Drugs) · 2017-09-20
- SevereBella Pharmaceuticals Recalls L-Glutamine Vials Due to Sterility Concerns
FDA (Drugs) · 2017-09-20
- SevereBella Pharmaceuticals Recalls Lidocaine Ophthalmic Gel Due to Sterility Concerns
FDA (Drugs) · 2017-09-20
Same hazard · sterility
See all →- HighFDA recalls injectable compounded mixture in single-use syringes
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SevereMedaus Recalls L-Glutathione Injection Due to Sterility Concerns
FDA (Drugs) · 2013-09-25
- SevereWellness Pharmacy Recalls RL Glutathione Due to Sterility Concerns
FDA (Drugs) · 2013-09-18
- SevereMedaus Recalls L-Glutathione Vials Due to Sterility Concerns
FDA (Drugs) · 2016-07-20
- SevereFDA Recalls L-Glutathione Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2013-05-22
- SevereLa Vita Compounding Pharmacy Recalls Glutathione Injection Due to Sterility Concerns
FDA (Drugs) · 2018-07-25
- SevereWells Pharmacy Recalls Glutathione Injectable Due to Sterility Concerns
FDA (Drugs) · 2017-01-11